One World Products' Isiah Thomas Issues Investor Update
NEWMEDIAWIRE) - One World Products, Inc. ('OWP') (OTCQB: OWPC), renowned for its innovative approach to eco-friendly materials, today announces that Chairman and CEO Isiah Thomas has issued the following investor update:
Dear Valued Shareholders,
I am pleased to share exciting updates on One World Products' progress as we position ourselves at the forefront of sustainable innovation in the automotive industry. Our company is making significant strides in utilizing industrial hemp to revolutionize automotive plastic applications, reinforcing our commitment to creating environmentally friendly and high-performance solutions for the global marketplace.
Expanding Our Presence in Automotive Plastic Applications
Our strategic focus on automotive applications is gaining momentum, and we are proud to be leading the charge in sustainable material innovations. By leveraging the unique benefits of industrial hemp, we are developing high-quality, lightweight, and durable solutions that directly address the automotive industry's increasing demand for eco-friendly materials. These innovations not only enhance vehicle efficiency and reduce carbon footprints but also position us to capture a significant share of a substantial market opportunity.
North America alone produced over 16 million vehicles in 2023, with each vehicle containing an average of 411 pounds of plastic components. This results in an annual total market opportunity of approximately 6.64 billion pounds of plastic, highlighting the immense growth potential available to One World Products as we further develop and commercialize our hemp-based materials.
Strategic Partnerships Driving Growth
We are thrilled to strengthen our partnerships with industry leaders Stellantis, West Michigan Compounding, and Flex-N-Gate. These collaborations are pivotal in accelerating the adoption of hemp-based materials across automotive manufacturing and supply chains. Through these alliances, we are integrating sustainable solutions that will drive innovation and create long-term value for our shareholders, customers, and stakeholders.
Our First Purchase Order with Flex-N-Gate
A major milestone for One World Products is our first purchase order with Flex-N-Gate, a testament to the growing demand for our industrial hemp applications. This order marks a significant step in validating the commercial viability of our materials and reinforces the trust that leading automotive manufacturers have in our ability to deliver sustainable, high-performance solutions. This achievement lays the foundation for future growth as we expand our product offerings and increase market penetration.
A New Name, A Bold Future
To better reflect our company's evolving focus and strategic direction, One World Products will soon undergo a name change. This transition is designed to align our brand identity with our mission and market focus, particularly in the automotive sector. We believe this new identity will more effectively communicate our vision to investors, partners, and the broader industry.
The momentum we are experiencing today is just the beginning. With our innovative product pipeline, strong industry partnerships, and commitment to sustainability, we are positioning ourselves as a leader in the next generation of automotive materials. We remain dedicated to delivering long-term shareholder value as we execute our growth strategy and expand our footprint in the global market.
Thank you for your continued support as we drive One World Products forward into this exciting new chapter.
Best regards,
Isiah Thomas
Chairman and CEO
One World Products, Inc.
For more information, please visit https://oneworldproducts.com #HempIsTheNewPlastic (TM)
Forward-Looking Statements:
This press release contains 'forward-looking statements.' Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential,' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ('SEC'), including the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at www.sec.gov.
All forward-looking statements speak only as of the date on which they are made. The Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement was made, except to the extent required by applicable securities laws.
800-605-3210 x506
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
22 minutes ago
- Business Wire
AG Mortgage Investment Trust, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call
NEW YORK--(BUSINESS WIRE)--AG Mortgage Investment Trust, Inc. (NYSE: MITT) (the 'Company') announced today that it will release second quarter 2025 financial results prior to market open on Friday, August 1, 2025. The Company will host a conference call to discuss the results on Friday, August 1, 2025, at 8:30 a.m. Eastern Time. To participate in the call by telephone, please dial (800) 274-8461 at least five minutes prior to the start time. International callers should dial (203) 518-9814. The Conference ID is MITTQ225. To listen to the live webcast of the conference call, please go to and register using the same Conference ID. A presentation will accompany the conference call and will be available prior to the call on the Company's website, under 'Presentations' in the 'News & Presentations' section. For those unable to listen to the live call, an audio replay will be available on August 1, 2025 through 9:00 a.m. Eastern Time on September 1, 2025. To access the replay, please go to the Company's website at About AG Mortgage Investment Trust, Inc. AG Mortgage Investment Trust, Inc. is a residential mortgage REIT with a focus on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. AG Mortgage Investment Trust, Inc. is externally managed and advised by AG REIT Management, LLC, a subsidiary of Angelo, Gordon & Co., L.P., a diversified credit and real estate investing platform within TPG. Additional information can be found on the Company's website at About TPG Angelo Gordon Founded in 1988, Angelo, Gordon & Co., L.P. ('TPG Angelo Gordon') is a diversified credit and real estate investing platform within TPG. The platform currently manages approximately $92 billion across a broad range of credit and real estate strategies. For more information, visit
Business Wire
22 minutes ago
- Business Wire
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the 'Company' or 'Delcath'), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to three individuals whose employment commenced in June 2025. The grants resulted in the right to purchase 52,500 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan ('Plan'). The options were granted on June 30, 2025, the date the Compensation Committee approved the stock option included within the equity inducements and are subject to an exercise price equal to $13.60, the closing price of Delcath's common stock on June 30, 2025. One-third of the options will vest on the first anniversary of the grant date with the remaining two-thirds of the options vesting in equal monthly installments over the following twenty-four months. The options have a ten-year term, and the vesting of the options are subject to the employee's continued employment with Delcath on each vesting date. The above-described awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and granted pursuant to the terms of the Plan. About Delcath Systems, Inc. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.
Business Wire
22 minutes ago
- Business Wire
Rosen Law Firm Urges Luminar Technologies, Inc. (NASDAQ: LAZR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Luminar Technologies, Inc. (NASDAQ: LAZR) securities between March 20, 2025 and May 14, 2025, both dates inclusive (the 'Class Period'). Luminar purports to be a technology company that specializes in advanced 'Light Detection and Ranging' ('LiDAR') hardware and software solutions for vehicles. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Luminar Technologies, Inc. (NASDAQ: LAZR) Misled Investors Regarding its Business Operations. According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Austin Russell ('Russell'), Luminar's President, CEO and Chairman of the Board, was engaged in undisclosed conduct that would make him the subject of an inquiry by the Audit Committee of the Board of Directors; (2) this conduct created material risk that Russell would be released form his positions at Luminar; (3) Luminar's loss of Russell as an employee would then create material risk of adversely affecting Luminar's business by making it more difficult to compete with other market participants, manage R&D activities, and retain existing customers or cultivate new ones. Further, negative public perception and negative news related to Russell could adversely affect Luminar's brand relationships with customers, or standing in the industry; (4) accordingly, Luminar had no reasonable basis to provide and/or maintain Luminar's financial guidance; and (5) as a result, defendants' public statements were materially false and/or misleading at all times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Luminar Technologies, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by September 22, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
